CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,631 | 233,476 | ||
| 2026-03-04 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +2,963 | $3.79 | $11K | 148,318 |
| 2026-03-04 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −2,963 | $18.25 | $54K | 145,355 |
| 2026-03-04 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,963 | 79,784 | ||
| 2026-03-04 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +16,300 | $3.79 | $62K | 71,586 |
| 2026-03-04 | Raben David Chief Medical Officer | Sale 10b5-1 | −16,300 | $18.52 | $302K | 55,286 |
| 2026-03-04 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,300 | 52,913 | ||
| 2026-03-03 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +12,892 | $3.79 | $49K | 222,533 |
| 2026-03-03 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −12,892 | $18.16 | $234K | 209,641 |
| 2026-03-03 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −4,500 | $18.16 | $82K | 205,141 |
| 2026-03-03 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,892 | 125,334 | ||
| 2026-03-03 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +7,318 | $3.79 | $28K | 152,673 |
| 2026-03-03 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +6,237 | $3.79 | $24K | 158,910 |
| 2026-03-03 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −13,555 | $18.22 | $247K | 145,355 |
| 2026-03-03 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,318 | 58,144 | ||
| 2026-03-03 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,237 | 82,747 | ||
| 2026-03-03 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +200 | $3.79 | $758 | 55,486 |
| 2026-03-03 | Raben David Chief Medical Officer | Sale 10b5-1 | −200 | $18.45 | $4K | 55,286 |
| 2026-03-03 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200 | 69,213 | ||
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +300,000 | $16.00 | $4.8M | 4,603,418 |
Page 6 of 14 · 276 trades